Seom guidelines for the treatment of gastric cancer 2015
Clin. transl. oncol. (Print)
; 17(12): 996-1004, dic. 2015. tab
Article
in En
| IBECS
| ID: ibc-147438
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced resectable tumor increase overall survival and should be considered standard treatments. In stage IV tumors, platinum-fluoropyrimidine-based schedule, with trastuzumab in HER2-overexpressed tumors, is the firstline treatment. Different therapies in second line have demonstrated in randomized studies their clear benefit in survival improvement (AU)
RESUMEN
No disponible
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Spain
/
Stomach Neoplasms
/
Barrett Esophagus
/
Adenocarcinoma
/
Helicobacter pylori
/
Lymph Nodes
/
Obesity
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2015
Document type:
Article